Evidence map›Paper›PMID 32523034›Full record

ReviewInternational journal of obesity (2005)2020

Potential therapeutic applications of the gut microbiome in obesity: from brain function to body detoxification.

Béatrice S-Y Choi, Laurence Daoust, Geneviève Pilon, André Marette, Angelo Tremblay

Abstract readReview
PubMed Publisher
In one paragraph

Review in International journal of obesity (2005), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. GLP-1 receptor agonism: a transformative approach for managing type-2 diabetes and obesity.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2025
    Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Béatrice S-Y Choi *Quebec Heart and Lung Institute, and Department of Medicine, Université Laval, Québec, QC, Canada.
Laurence Daoust *Quebec Heart and Lung Institute, and Department of Medicine, Université Laval, Québec, QC, Canada.
Geneviève PilonQuebec Heart and Lung Institute, and Department of Medicine, Université Laval, Québec, QC, Canada.
André MaretteQuebec Heart and Lung Institute, and Department of Medicine, Université Laval, Québec, QC, Canada.ORCID http://orcid.org/0000-0003-3950-5973
Angelo TremblayQuebec Heart and Lung Institute, and Department of Medicine, Université Laval, Québec, QC, Canada. angelo.tremblay@kin.ulaval.ca.
Université Laval · CALung Institute · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The prevalence of obesity is rising every year and associated comorbidities such as cardiovascular diseases are among the leading causes of death worldwide. The gut microbiota has recently emerged as a potential target for therapeutic applications to prevent and treat those comorbidities. In this review, we focus on three conditions related to obesity in which the use of gut microbiota modulators could have benefits; mood disorders, eating behaviors, and body detoxification of persistent organic pollutants (POPs). On one hand, modulation of gut-derived signals to the brain in a context of obesity is involved in the development of neuroinflammation and can subsequently alter behaviors. An altered gut microbiome could change these signals and alleviate their consequences. On the other hand, obesity is associated with an increased accumulation of lipophilic contaminants, such as POPs. Targeting the microbiota could help body detoxication by reducing bioavailability, enhancing degradation by bioremediation or their excretion through the enterohepatic circulation. Thus, a supplementation of prebiotics, probiotics, or synbiotics could represent a complementary strategy to current ones, such as medication and lifestyle modifications, to decrease depression, alter eating behaviors, and lower body burden of pollutants considering the actual obesity epidemic our society is facing.

Indexed as

ObesityBrainDietary SupplementsGastrointestinal MicrobiomeHumansPrebioticsProbioticsSynbioticsPrebiotics

Identifiers

PMID32523034
OpenAlexW3033224564

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.